Summit Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines to treat rare diseases with high unmet medical need. The company's lead product candidate, Ridinilazole, is a precision antibiotic that has the potential to treat Clostridium difficile infection (CDI) with a superior clinical profile compared to existing CDI treatments. Summit Therapeutics is also developing a pipeline of additional product candidates targeting genetic diseases and other indications.